Neurol. praxi. 2026;27(4):273-277 | DOI: 10.36290/neu.2026.051

Myoclonus - treatment: from rational pharmacotherapy to deep brain stimulation

doc. MUDr. Marek Baláž, Ph.D.1, MUDr. Pavel Ressner, Ph.D.1, prof. MUDr. Jan Chrastina, Ph.D.2, MUDr. Jonáš Kunst1
1 I. neurologická klinika LF MU, FN u sv. Anny v Brně
2 Neurochirurgická klinika, FN u sv. Anny v Brně

The basis of successful myoclonus treatment lies in diagnosing the underlying causes, particularly ruling out drug-induced forms and metabolic disorders. The mainstays of symptomatic therapy are levetiracetam, valproate, and clonazepam, often in combination, while in drug-resistant cases, particularly in myoclonic dystonia, deep brain stimulation (DBS), most commonly targeting the globus pallidus internus, represents a significant therapeutic alternative. In focal forms, long-term therapy involves the administration of botulinum toxin.

Keywords: myoclonus, therapy of myoclonus, pharmacotherapy, deep brain stimulation, botulinum toxin.

Received: May 27, 2026; Revised: September 1, 2026; Accepted: September 3, 2026; Published: October 2, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Baláž M, Ressner P, Chrastina J, Kunst J. Myoclonus - treatment: from rational pharmacotherapy to deep brain stimulation. Neurol. praxi. 2026;27(4):273-277. doi: 10.36290/neu.2026.051.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 2.10.2027

    References

    1. Albanese A, Barnes MP, Bhatia KP, et al. A systematic review on the clinical use of botulinum toxin in movement disorders. Eur J Neurol. 2015;22:16-24.
    2. Baláž M, Bočková M. Myoklonus. Neurol. praxi. 2011;12(1):22-25.
    3. Bareš M, Muchová M, Kaňovský P, et al. Myoklonus - srovnání účinnosti léčby podle typu ovlivněných neurotransmiterových systémů. Neurol. praxi. 2006;1:46-48.
    4. Caviness JN. Treatment of myoclonus. Neurotherapeutics. 2014;11:188-200. Go to original source... Go to PubMed...
    5. Chiang CC, Masterson R, T Nguyen E, et al. Rehabilitation considerations for palato-pharyngo-laryngeal myoclonus associated dysphagia. PM R. 2024;16(8):938-940. Go to original source...
    6. De Santis T, Mogilner AY, Pourfar M. Post-Hypoxic Myoclonus and Deep Brain Stimulation. Experience from a Small Patient Cohort and Literature Review Highlighting Variable Outcomes. Tremor Other Hyperkinet Mov (N Y). 2026;16:43. doi: 10.5334/tohm.1171. Go to original source... Go to PubMed...
    7. Dressler D, Altavista MC, Altenmueller E, et al. Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. J Neural Transm (Vienna). 2021;128(3):321-335. doi: 10.1007/s00702-021-02312-4. Go to original source... Go to PubMed...
    8. Friedreich N. Paramyoclonus multiplex. Neuropathologische Beobachtungen. Arch Path Anat (Virchow Arch). 1881;86:421-434. Go to original source...
    9. Ginker RR, Serota H, Stein SI. Myoclonic epilepsy. Arch Neurol Psychiatry. 1938;40:968-980. Go to original source...
    10. Hainque E, Vidailhet M, Cozic N, et al. A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia. Neurology. 2016;86(18):1729-1735. Go to original source...
    11. Holmes GL. Drug Treatment of Progressive Myoclonic Epilepsy. Paediatr Drugs. 2020Apr; 22(2): 149-164. Go to original source... Go to PubMed...
    12. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004;75:951-957. Go to original source... Go to PubMed...
    13. Jech R. Myoklonus a jeho diferenciální diagnostika. Postgraduální medicína. 2006;8(5):523-528.
    14. Kojovic M, Cordivari C, Bhatia K. Myoclonic disorders: a practical approach. Lancet Neurol. 2011;10:104-117.
    15. Kosutzka Z, Tisch S, Bonnet C, et al. Long-term GPi-DBS improves motor features in myoclonus-dystonia and enhances social adjustment. Mov Disord. 2019;34(1):87-94. Go to original source... Go to PubMed...
    16. Rissardo JP, Fornari Caprara AL, et al. Drug-Induced Myoclonus: A Systematic Review. Medicina. 2025; 61(1):131. Go to original source...
    17. Riva A, D'Onofrio G, Ferlazzo E, et al. Myoclonus: Differential diagnosis and current management. Epilepsia Open. 2024; 9(2):486-500. Go to original source...
    18. Roze E, Vidailhet M, Hubsch C, et al. Pallidal stimulation for myoclonus-dystonia: Ten years' outcome in two patients. Mov Disord. 2015;30(6):871-872. Go to original source... Go to PubMed...
    19. Shumway-Cook A, Woollacott MH. Motor Control, 5e. Lippincott Williams & Wilkins, a Wolters Kluwer bu; 2017.
    20. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update: botulinum neurotoxin for the treatment of movement disorders. Neurology. 2016;86:1818-1826. Go to original source... Go to PubMed...
    21. Volkmann J, Herzog J, Kopper F, et al. Introduction to the programming of deep brain stimulators. Mov Disord. 2002;17(S3):S181-S187. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.